<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240325221430&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240325221430&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 26 Mar 2024 02:14:31 +0000</lastbuilddate>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Can an implantable loop recorder improve risk stratification and appropriate management in Brugada syndrome?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527218/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 25:ehae136. doi: 10.1093/eurheartj/ehae136. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527218/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527218</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae136>10.1093/eurheartj/ehae136</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527218</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Fiorenzo Gaita</dc:creator>
<dc:creator>Natascia Cerrato</dc:creator>
<dc:creator>Carla Giustetto</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Can an implantable loop recorder improve risk stratification and appropriate management in Brugada syndrome?</dc:title>
<dc:identifier>pmid:38527218</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae136</dc:identifier>
</item>
<item>
<title>Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and Benefits</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527139/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):989-992. doi: 10.1161/CIRCULATIONAHA.123.067919. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527139/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527139</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067919>10.1161/CIRCULATIONAHA.123.067919</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527139</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Siddharth M Patel</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and Benefits</dc:title>
<dc:identifier>pmid:38527139</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067919</dc:identifier>
</item>
<item>
<title>Correction to: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527138/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1023. doi: 10.1161/CIR.0000000000001241. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527138/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527138</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001241>10.1161/CIR.0000000000001241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527138</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:38527138</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001241</dc:identifier>
</item>
<item>
<title>Retraction of: Abstract 13079: Prevalence and Incidence of Transthyretin Amyloid Cardiomyopathy in the USA From 2004 to 2022: An Observational Database Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527137/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1027. doi: 10.1161/CIR.0000000000001239. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527137/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527137</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001239>10.1161/CIR.0000000000001239</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527137</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Retraction of: Abstract 13079: Prevalence and Incidence of Transthyretin Amyloid Cardiomyopathy in the USA From 2004 to 2022: An Observational Database Study</dc:title>
<dc:identifier>pmid:38527137</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001239</dc:identifier>
</item>
<item>
<title>Atrial Fibrillation: Why Are We Hiding Reality?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):979-980. doi: 10.1161/CIRCULATIONAHA.123.067544. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527136</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067544>10.1161/CIRCULATIONAHA.123.067544</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527136</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>James A Reiffel</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Atrial Fibrillation: Why Are We Hiding Reality?</dc:title>
<dc:identifier>pmid:38527136</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067544</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18539</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1025. doi: 10.1161/CIR.0000000000001237. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527135</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001237>10.1161/CIR.0000000000001237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527135</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18539</dc:title>
<dc:identifier>pmid:38527135</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001237</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 15684</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1024. doi: 10.1161/CIR.0000000000001238. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527134</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001238>10.1161/CIR.0000000000001238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527134</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 15684</dc:title>
<dc:identifier>pmid:38527134</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001238</dc:identifier>
</item>
<item>
<title>Aggregation and Contextualization of Murine Investigations Improves Discovery of Significant Human Atherosclerotic Cardiovascular Disease Associations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):1056-1058. doi: 10.1161/CIRCULATIONAHA.123.067510. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527133</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067510>10.1161/CIRCULATIONAHA.123.067510</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527133</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan M Shuey</dc:creator>
<dc:creator>Yihua Wang</dc:creator>
<dc:creator>Rachel R Xiang</dc:creator>
<dc:creator>Aaron Zou</dc:creator>
<dc:creator>Protiva Rahman</dc:creator>
<dc:creator>Daniel Fabbri</dc:creator>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:creator>Iris Z Jaffe</dc:creator>
<dc:creator>Quinn S Wells</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Aggregation and Contextualization of Murine Investigations Improves Discovery of Significant Human Atherosclerotic Cardiovascular Disease Associations</dc:title>
<dc:identifier>pmid:38527133</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067510</dc:identifier>
</item>
<item>
<title>Don't Judge A Book By Its Cover</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):1053-1055. doi: 10.1161/CIRCULATIONAHA.123.068148. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527132</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068148>10.1161/CIRCULATIONAHA.123.068148</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527132</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Saurabh Deshpande</dc:creator>
<dc:creator>Rajesh Rajani</dc:creator>
<dc:creator>Ameya Udyavar</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Don't Judge A Book By Its Cover</dc:title>
<dc:identifier>pmid:38527132</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068148</dc:identifier>
</item>
<item>
<title>Correction to: International Collaboration Identifies Gene Linked to Congenital Heart Defect</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527131/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1026. doi: 10.1161/CIR.0000000000001236. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527131/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527131</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001236>10.1161/CIR.0000000000001236</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527131</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: International Collaboration Identifies Gene Linked to Congenital Heart Defect</dc:title>
<dc:identifier>pmid:38527131</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001236</dc:identifier>
</item>
<item>
<title>Scrutinizing the Role of Venoarterial Extracorporeal Membrane Oxygenation: Has Clinical Practice Outpaced the Evidence?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support in various clinical scenarios has been increasing consistently, despite the lack of sufficient evidence regarding its benefit and safety from adequately powered randomized controlled trials. Although the ARREST trial (Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation) and a secondary analysis of the PRAGUE OHCA...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):1033-1052. doi: 10.1161/CIRCULATIONAHA.123.067087. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support in various clinical scenarios has been increasing consistently, despite the lack of sufficient evidence regarding its benefit and safety from adequately powered randomized controlled trials. Although the ARREST trial (Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation) and a secondary analysis of the PRAGUE OHCA trial (Prague Out-of-Hospital Cardiac Arrest) provided some evidence in favor of VA-ECMO in the setting of out-of-hospital cardiac arrest, the INCEPTION trial (Early Initiation of Extracorporeal Life Support in Refractory Out-of-Hospital Cardiac Arrest) has not found a relevant improvement of short-term mortality with extracorporeal cardiopulmonary resuscitation. In addition, the results of the recently published ECLS-SHOCK trial (Extracorporeal Life Support in Cardiogenic Shock) and ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) discourage the routine use of VA-ECMO in patients with infarct-related cardiogenic shock. Ongoing clinical trials (ANCHOR [Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock, NCT04184635], REVERSE [Impella CP With VA ECMO for Cardiogenic Shock, NCT03431467], UNLOAD ECMO [Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO, NCT05577195], PIONEER [Hemodynamic Support With ECMO and IABP in Elective Complex High-risk PCI, NCT04045873]) may clarify the usefulness of VA-ECMO in specific patient subpopulations and the efficacy of combined mechanical circulatory support strategies. Pending further data to refine patient selection and management recommendations for VA-ECMO, it remains uncertain whether the present usage of this device improves outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527130</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067087>10.1161/CIRCULATIONAHA.123.067087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527130</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Enzo Lüsebrink</dc:creator>
<dc:creator>Leonhard Binzenhöfer</dc:creator>
<dc:creator>Daniel Hering</dc:creator>
<dc:creator>Laura Villegas Sierra</dc:creator>
<dc:creator>Benedikt Schrage</dc:creator>
<dc:creator>Clemens Scherer</dc:creator>
<dc:creator>Walter S Speidl</dc:creator>
<dc:creator>Aitor Uribarri</dc:creator>
<dc:creator>Manel Sabate</dc:creator>
<dc:creator>Marko Noc</dc:creator>
<dc:creator>Elena Sandoval</dc:creator>
<dc:creator>Andrejs Erglis</dc:creator>
<dc:creator>Federico Pappalardo</dc:creator>
<dc:creator>Frederic De Roeck</dc:creator>
<dc:creator>Guido Tavazzi</dc:creator>
<dc:creator>Jordi Riera</dc:creator>
<dc:creator>Roberto Roncon-Albuquerque</dc:creator>
<dc:creator>Benjamin Meder</dc:creator>
<dc:creator>Peter Luedike</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Christian Hagl</dc:creator>
<dc:creator>Sebastian Zimmer</dc:creator>
<dc:creator>Dirk Westermann</dc:creator>
<dc:creator>Alain Combes</dc:creator>
<dc:creator>Uwe Zeymer</dc:creator>
<dc:creator>Steffen Massberg</dc:creator>
<dc:creator>Andreas Schäfer</dc:creator>
<dc:creator>Martin Orban</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Scrutinizing the Role of Venoarterial Extracorporeal Membrane Oxygenation: Has Clinical Practice Outpaced the Evidence?</dc:title>
<dc:identifier>pmid:38527130</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067087</dc:identifier>
</item>
<item>
<title>How Can Young Extracellular Matrix Promote Cardiac Regeneration? Versi-Can!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527129/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):1016-1018. doi: 10.1161/CIRCULATIONAHA.123.068078. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527129/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527129</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068078>10.1161/CIRCULATIONAHA.123.068078</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527129</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Elad Bassat</dc:creator>
<dc:creator>Eldad Tzahor</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>How Can Young Extracellular Matrix Promote Cardiac Regeneration? Versi-Can!</dc:title>
<dc:identifier>pmid:38527129</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068078</dc:identifier>
</item>
<item>
<title>The American Heart Association's Centennial and Percutaneous Coronary Intervention's Semi-Centennial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527128/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):973-978. doi: 10.1161/CIRCULATIONAHA.123.064461. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527128/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38527128</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064461>10.1161/CIRCULATIONAHA.123.064461</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527128</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>Pruthvi C Revaiah</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The American Heart Association's Centennial and Percutaneous Coronary Intervention's Semi-Centennial</dc:title>
<dc:identifier>pmid:38527128</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064461</dc:identifier>
</item>
<item>
<title>Single-cell dissection of the human motor and prefrontal cortices in ALS and FTLD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38521060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) share many clinical, pathological, and genetic features, but a detailed understanding of their associated transcriptional alterations across vulnerable cortical cell types is lacking. Here, we report a high-resolution, comparative single-cell molecular atlas of the human primary motor and dorsolateral prefrontal cortices and their transcriptional alterations in sporadic and familial ALS and FTLD. By integrating...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 14:S0092-8674(24)00234-4. doi: 10.1016/j.cell.2024.02.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) share many clinical, pathological, and genetic features, but a detailed understanding of their associated transcriptional alterations across vulnerable cortical cell types is lacking. Here, we report a high-resolution, comparative single-cell molecular atlas of the human primary motor and dorsolateral prefrontal cortices and their transcriptional alterations in sporadic and familial ALS and FTLD. By integrating transcriptional and genetic information, we identify known and previously unidentified vulnerable populations in cortical layer 5 and show that ALS- and FTLD-implicated motor and spindle neurons possess a virtually indistinguishable molecular identity. We implicate potential disease mechanisms affecting these cell types as well as non-neuronal drivers of pathogenesis. Finally, we show that neuron loss in cortical layer 5 tracks more closely with transcriptional identity rather than cellular morphology and extends beyond previously reported vulnerable cell types.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38521060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38521060</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.031>10.1016/j.cell.2024.02.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38521060</guid>
<pubDate>Sat, 23 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>S Sebastian Pineda</dc:creator>
<dc:creator>Hyeseung Lee</dc:creator>
<dc:creator>Maria J Ulloa-Navas</dc:creator>
<dc:creator>Raleigh M Linville</dc:creator>
<dc:creator>Francisco J Garcia</dc:creator>
<dc:creator>Kyriakitsa Galani</dc:creator>
<dc:creator>Erica Engelberg-Cook</dc:creator>
<dc:creator>Monica C Castanedes</dc:creator>
<dc:creator>Brent E Fitzwalter</dc:creator>
<dc:creator>Luc J Pregent</dc:creator>
<dc:creator>Mahammad E Gardashli</dc:creator>
<dc:creator>Michael DeTure</dc:creator>
<dc:creator>Diana V Vera-Garcia</dc:creator>
<dc:creator>Andre T S Hucke</dc:creator>
<dc:creator>Bjorn E Oskarsson</dc:creator>
<dc:creator>Melissa E Murray</dc:creator>
<dc:creator>Dennis W Dickson</dc:creator>
<dc:creator>Myriam Heiman</dc:creator>
<dc:creator>Veronique V Belzil</dc:creator>
<dc:creator>Manolis Kellis</dc:creator>
<dc:date>2024-03-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Single-cell dissection of the human motor and prefrontal cortices in ALS and FTLD</dc:title>
<dc:identifier>pmid:38521060</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.031</dc:identifier>
</item>
<item>
<title>Biofilm exopolysaccharides alter sensory-neuron-mediated sickness during lung infection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38518773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>Infections of the lung cause observable sickness thought to be secondary to inflammation. Signs of sickness are crucial to alert others via behavioral-immune responses to limit contact with contagious individuals. Gram-negative bacteria produce exopolysaccharide (EPS) that provides microbial protection; however, the impact of EPS on sickness remains uncertain. Using genome-engineered Pseudomonas aeruginosa (P. aeruginosa) strains, we compared EPS-producers versus non-producers and a virulent...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 13:S0092-8674(24)00249-6. doi: 10.1016/j.cell.2024.03.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Infections of the lung cause observable sickness thought to be secondary to inflammation. Signs of sickness are crucial to alert others via behavioral-immune responses to limit contact with contagious individuals. Gram-negative bacteria produce exopolysaccharide (EPS) that provides microbial protection; however, the impact of EPS on sickness remains uncertain. Using genome-engineered Pseudomonas aeruginosa (P. aeruginosa) strains, we compared EPS-producers versus non-producers and a virulent Escherichia coli (E. coli) lung infection model in male and female mice. EPS-negative P. aeruginosa and virulent E. coli infection caused severe sickness, behavioral alterations, inflammation, and hypothermia mediated by TLR4 detection of the exposed lipopolysaccharide (LPS) in lung TRPV1<sup>+</sup> sensory neurons. However, inflammation did not account for sickness. Stimulation of lung nociceptors induced acute stress responses in the paraventricular hypothalamic nuclei by activating corticotropin-releasing hormone neurons responsible for sickness behavior and hypothermia. Thus, EPS-producing biofilm pathogens evade initiating a lung-brain sensory neuronal response that results in sickness.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38518773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38518773</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.001>10.1016/j.cell.2024.03.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38518773</guid>
<pubDate>Fri, 22 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Elise Granton</dc:creator>
<dc:creator>Luke Brown</dc:creator>
<dc:creator>Manon Defaye</dc:creator>
<dc:creator>Parisa Moazen</dc:creator>
<dc:creator>Henrik Almblad</dc:creator>
<dc:creator>Trevor E Randall</dc:creator>
<dc:creator>Jacquelyn D Rich</dc:creator>
<dc:creator>Andrew Geppert</dc:creator>
<dc:creator>Nasser S Abdullah</dc:creator>
<dc:creator>Mortaza F Hassanabad</dc:creator>
<dc:creator>Carlos H Hiroki</dc:creator>
<dc:creator>Raquel Farias</dc:creator>
<dc:creator>Angela P Nguyen</dc:creator>
<dc:creator>Courtney Schubert</dc:creator>
<dc:creator>Yuefei Lou</dc:creator>
<dc:creator>Graciela Andonegui</dc:creator>
<dc:creator>Mircea Iftinca</dc:creator>
<dc:creator>Deepa Raju</dc:creator>
<dc:creator>Mario A Vargas</dc:creator>
<dc:creator>P Lynne Howell</dc:creator>
<dc:creator>Tamás Füzesi</dc:creator>
<dc:creator>Jaideep Bains</dc:creator>
<dc:creator>Deborah Kurrasch</dc:creator>
<dc:creator>Joe Jonathan Harrison</dc:creator>
<dc:creator>Christophe Altier</dc:creator>
<dc:creator>Bryan G Yipp</dc:creator>
<dc:date>2024-03-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Biofilm exopolysaccharides alter sensory-neuron-mediated sickness during lung infection</dc:title>
<dc:identifier>pmid:38518773</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.001</dc:identifier>
</item>
<item>
<title>Task-driven neural network models predict neural dynamics of proprioception</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38518772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>Proprioception tells the brain the state of the body based on distributed sensory neurons. Yet, the principles that govern proprioceptive processing are poorly understood. Here, we employ a task-driven modeling approach to investigate the neural code of proprioceptive neurons in cuneate nucleus (CN) and somatosensory cortex area 2 (S1). We simulated muscle spindle signals through musculoskeletal modeling and generated a large-scale movement repertoire to train neural networks based on 16...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 18:S0092-8674(24)00239-3. doi: 10.1016/j.cell.2024.02.036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Proprioception tells the brain the state of the body based on distributed sensory neurons. Yet, the principles that govern proprioceptive processing are poorly understood. Here, we employ a task-driven modeling approach to investigate the neural code of proprioceptive neurons in cuneate nucleus (CN) and somatosensory cortex area 2 (S1). We simulated muscle spindle signals through musculoskeletal modeling and generated a large-scale movement repertoire to train neural networks based on 16 hypotheses, each representing different computational goals. We found that the emerging, task-optimized internal representations generalize from synthetic data to predict neural dynamics in CN and S1 of primates. Computational tasks that aim to predict the limb position and velocity were the best at predicting the neural activity in both areas. Since task optimization develops representations that better predict neural activity during active than passive movements, we postulate that neural activity in the CN and S1 is top-down modulated during goal-directed movements.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38518772/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38518772</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.036>10.1016/j.cell.2024.02.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38518772</guid>
<pubDate>Fri, 22 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Alessandro Marin Vargas</dc:creator>
<dc:creator>Axel Bisi</dc:creator>
<dc:creator>Alberto S Chiappa</dc:creator>
<dc:creator>Chris Versteeg</dc:creator>
<dc:creator>Lee E Miller</dc:creator>
<dc:creator>Alexander Mathis</dc:creator>
<dc:date>2024-03-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Task-driven neural network models predict neural dynamics of proprioception</dc:title>
<dc:identifier>pmid:38518772</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.036</dc:identifier>
</item>
<item>
<title>Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38513664/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>Multiple sclerosis (MS) is a neurological disease characterized by multifocal lesions and smoldering pathology. Although single-cell analyses provided insights into cytopathology, evolving cellular processes underlying MS remain poorly understood. We investigated the cellular dynamics of MS by modeling temporal and regional rates of disease progression in mouse experimental autoimmune encephalomyelitis (EAE). By performing single-cell spatial expression profiling using in situ sequencing (ISS),...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 14:S0092-8674(24)00233-2. doi: 10.1016/j.cell.2024.02.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Multiple sclerosis (MS) is a neurological disease characterized by multifocal lesions and smoldering pathology. Although single-cell analyses provided insights into cytopathology, evolving cellular processes underlying MS remain poorly understood. We investigated the cellular dynamics of MS by modeling temporal and regional rates of disease progression in mouse experimental autoimmune encephalomyelitis (EAE). By performing single-cell spatial expression profiling using in situ sequencing (ISS), we annotated disease neighborhoods and found centrifugal evolution of active lesions. We demonstrated that disease-associated (DA)-glia arise independently of lesions and are dynamically induced and resolved over the disease course. Single-cell spatial mapping of human archival MS spinal cords confirmed the differential distribution of homeostatic and DA-glia, enabled deconvolution of active and inactive lesions into sub-compartments, and identified new lesion areas. By establishing a spatial resource of mouse and human MS neuropathology at a single-cell resolution, our study unveils the intricate cellular dynamics underlying MS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38513664/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38513664</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.030>10.1016/j.cell.2024.02.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38513664</guid>
<pubDate>Thu, 21 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Petra Kukanja</dc:creator>
<dc:creator>Christoffer M Langseth</dc:creator>
<dc:creator>Leslie A Rubio Rodríguez-Kirby</dc:creator>
<dc:creator>Eneritz Agirre</dc:creator>
<dc:creator>Chao Zheng</dc:creator>
<dc:creator>Amitha Raman</dc:creator>
<dc:creator>Chika Yokota</dc:creator>
<dc:creator>Christophe Avenel</dc:creator>
<dc:creator>Katarina Tiklová</dc:creator>
<dc:creator>André O Guerreiro-Cacais</dc:creator>
<dc:creator>Tomas Olsson</dc:creator>
<dc:creator>Markus M Hilscher</dc:creator>
<dc:creator>Mats Nilsson</dc:creator>
<dc:creator>Gonçalo Castelo-Branco</dc:creator>
<dc:date>2024-03-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology</dc:title>
<dc:identifier>pmid:38513664</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.030</dc:identifier>
</item>
<item>
<title>Transport mechanism and pharmacology of the human GlyT1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38513663/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>The glycine transporter 1 (GlyT1) plays a crucial role in the regulation of both inhibitory and excitatory neurotransmission by removing glycine from the synaptic cleft. Given its close association with glutamate/glycine co-activated NMDA receptors (NMDARs), GlyT1 has emerged as a central target for the treatment of schizophrenia, which is often linked to hypofunctional NMDARs. Here, we report the cryo-EM structures of GlyT1 bound with substrate glycine and drugs ALX-5407, SSR504734, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 13:S0092-8674(24)00228-9. doi: 10.1016/j.cell.2024.02.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The glycine transporter 1 (GlyT1) plays a crucial role in the regulation of both inhibitory and excitatory neurotransmission by removing glycine from the synaptic cleft. Given its close association with glutamate/glycine co-activated NMDA receptors (NMDARs), GlyT1 has emerged as a central target for the treatment of schizophrenia, which is often linked to hypofunctional NMDARs. Here, we report the cryo-EM structures of GlyT1 bound with substrate glycine and drugs ALX-5407, SSR504734, and PF-03463275. These structures, captured at three fundamental states of the transport cycle-outward-facing, occluded, and inward-facing-enable us to illustrate a comprehensive blueprint of the conformational change associated with glycine reuptake. Additionally, we identified three specific pockets accommodating drugs, providing clear insights into the structural basis of their inhibitory mechanism and selectivity. Collectively, these structures offer significant insights into the transport mechanism and recognition of substrate and anti-schizophrenia drugs, thus providing a platform to design small molecules to treat schizophrenia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38513663/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38513663</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.026>10.1016/j.cell.2024.02.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38513663</guid>
<pubDate>Thu, 21 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yiqing Wei</dc:creator>
<dc:creator>Renjie Li</dc:creator>
<dc:creator>Yufei Meng</dc:creator>
<dc:creator>Tuo Hu</dc:creator>
<dc:creator>Jun Zhao</dc:creator>
<dc:creator>Yiwei Gao</dc:creator>
<dc:creator>Qinru Bai</dc:creator>
<dc:creator>Na Li</dc:creator>
<dc:creator>Yan Zhao</dc:creator>
<dc:date>2024-03-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Transport mechanism and pharmacology of the human GlyT1</dc:title>
<dc:identifier>pmid:38513663</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.026</dc:identifier>
</item>
<item>
<title>Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38513060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients at risk of renal injury undergoing coronary angiography for ACS, a short (5 day) course of once-daily inorganic nitrate reduced CIN, improved kidney outcomes at 3 months, and MACE events at 1 year compared to placebo.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 21:ehae100. doi: 10.1093/eurheartj/ehae100. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Contrast-induced nephropathy (CIN), also known as contrast-associated acute kidney injury (CA-AKI) underlies a significant proportion of the morbidity and mortality following coronary angiographic procedures in high-risk patients and remains a significant unmet need. In pre-clinical studies inorganic nitrate, which is chemically reduced in vivo to nitric oxide, is renoprotective but this observation is yet to be translated clinically. In this study, the efficacy of inorganic nitrate in the prevention of CIN in high-risk patients presenting with acute coronary syndromes (ACS) is reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: NITRATE-CIN is a double-blind, randomized, single-centre, placebo-controlled trial assessing efficacy of inorganic nitrate in CIN prevention in at-risk patients presenting with ACS. Patients were randomized 1:1 to once daily potassium nitrate (12 mmol) or placebo (potassium chloride) capsules for 5 days. The primary endpoint was CIN (KDIGO criteria). Secondary outcomes included kidney function [estimated glomerular filtration rate (eGFR)] at 3 months, rates of procedural myocardial infarction, and major adverse cardiac events (MACE) at 12 months. This study is registered with ClinicalTrials.gov: NCT03627130.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over 3 years, 640 patients were randomized with a median follow-up of 1.0 years, 319 received inorganic nitrate with 321 received placebo. The mean age of trial participants was 71.0 years, with 73.3% male and 75.2% Caucasian; 45.9% had diabetes, 56.0% had chronic kidney disease (eGFR &lt;60 mL/min) and the mean Mehran score of the population was 10. Inorganic nitrate treatment significantly reduced CIN rates (9.1%) vs. placebo (30.5%, P &lt; .001). This difference persisted after adjustment for baseline creatinine and diabetes status (odds ratio 0.21, 95% confidence interval 0.13-0.34). Secondary outcomes were improved with inorganic nitrate, with lower rates of procedural myocardial infarction (2.7% vs. 12.5%, P = .003), improved 3-month renal function (between-group change in eGFR 5.17, 95% CI 2.94-7.39) and reduced 1-year MACE (9.1% vs. 18.1%, P = .001) vs. placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients at risk of renal injury undergoing coronary angiography for ACS, a short (5 day) course of once-daily inorganic nitrate reduced CIN, improved kidney outcomes at 3 months, and MACE events at 1 year compared to placebo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38513060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38513060</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae100>10.1093/eurheartj/ehae100</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38513060</guid>
<pubDate>Thu, 21 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel A Jones</dc:creator>
<dc:creator>Anne-Marie Beirne</dc:creator>
<dc:creator>Matthew Kelham</dc:creator>
<dc:creator>Lucinda Wynne</dc:creator>
<dc:creator>Mervyn Andiapen</dc:creator>
<dc:creator>Krishnaraj S Rathod</dc:creator>
<dc:creator>Tipparat Parakaw</dc:creator>
<dc:creator>Jessica Adams</dc:creator>
<dc:creator>Annastazia Learoyd</dc:creator>
<dc:creator>Kamran Khan</dc:creator>
<dc:creator>Thomas Godec</dc:creator>
<dc:creator>Paul Wright</dc:creator>
<dc:creator>Sotiris Antoniou</dc:creator>
<dc:creator>Andrew Wragg</dc:creator>
<dc:creator>Muhammad Yaqoob</dc:creator>
<dc:creator>Anthony Mathur</dc:creator>
<dc:creator>Amrita Ahluwalia</dc:creator>
<dc:date>2024-03-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial</dc:title>
<dc:identifier>pmid:38513060</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae100</dc:identifier>
</item>
<item>
<title>Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38509244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities. For those with gastrointestinal bleeding (GIB), we summarize a general scheme for risk stratification...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 20. doi: 10.1038/s41569-024-01003-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities. For those with gastrointestinal bleeding (GIB), we summarize a general scheme for risk stratification and clinical evidence on risk reduction approaches, such as limiting the use of concomitant medications that increase the risk of GIB and the potential utility of gastrointestinal protection strategies (such as proton pump inhibitors or histamine type 2 receptor antagonists). Furthermore, we summarize the best available evidence and potential gaps in our knowledge on tailoring antithrombotic therapy in patients with active or recent GIB and in those at high risk of GIB but without active or recent GIB. Finally, we review the recommendations provided by major medical societies, highlighting the crucial role of teamwork and multidisciplinary discussions to customize the antithrombotic regimen in patients with coexisting cardiovascular and gastrointestinal diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38509244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38509244</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01003-3>10.1038/s41569-024-01003-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38509244</guid>
<pubDate>Thu, 21 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Azita H Talasaz</dc:creator>
<dc:creator>Parham Sadeghipour</dc:creator>
<dc:creator>Luis Ortega-Paz</dc:creator>
<dc:creator>Hessam Kakavand</dc:creator>
<dc:creator>Maryam Aghakouchakzadeh</dc:creator>
<dc:creator>Craig Beavers</dc:creator>
<dc:creator>John Fanikos</dc:creator>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>Deborah M Siegal</dc:creator>
<dc:creator>Manuel Monreal</dc:creator>
<dc:creator>David Jimenez</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Lana A Castellucci</dc:creator>
<dc:creator>Adam Cuker</dc:creator>
<dc:creator>Geoffrey D Barnes</dc:creator>
<dc:creator>Jean M Connors</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:creator>Benjamin W Van Tassell</dc:creator>
<dc:creator>Raffaele De Caterina</dc:creator>
<dc:creator>Jacob E Kurlander</dc:creator>
<dc:creator>Ali Aminian</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:creator>Samuel Z Goldhaber</dc:creator>
<dc:creator>Lisa Moores</dc:creator>
<dc:creator>Saskia Middeldorp</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Stavros Konstantinides</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Mary Cushman</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2024-03-21</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease</dc:title>
<dc:identifier>pmid:38509244</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01003-3</dc:identifier>
</item>
<item>
<title>Reply: Aging in Patients With Fontan Circulation: Raison d'être of Right Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240325221430&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):e119. doi: 10.1016/j.jacc.2024.01.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240325221430&v=2.18.0.post9+e462414">38508853</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.022>10.1016/j.jacc.2024.01.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508853</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Rani Zierath</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Aging in Patients With Fontan Circulation: Raison d'être of Right Ventricle</dc:title>
<dc:identifier>pmid:38508853</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.022</dc:identifier>
</item>





























</channel>
</rss>